Medicenna Therapeutics Corp.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Fahar Merchant
- Full Time Employees
- 20
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 2 Bloor Street West Toronto ON Canada M4W 3E2
- IPO Date
- Jul 13, 2015
- Website
- medicenna.com
- Similar Companies
- Business
- Medicenna Therapeutics Corp. Medicenna Therapeutics Corp. (MDNA.TO) is a clinical-stage immunotherapy company that develops highly selective Superkines, engineered interleukins including IL-2, IL-4, and IL-13 variants, and first-in-class Empowered Superkines designed to modulate the immune system for treating cancer, autoimmune diseases, and immune-mediated conditions; core pipeline assets encompass MDNA11, a long-acting IL-2 Superkine with superior CD122 affinity and no CD25 binding that preferentially activates cancer-killing effector T cells and NK cells in Phase 1/2 trials for solid tumors such as melanoma and cutaneous squamous cell carcinoma, bizaxofusp (formerly MDNA55), an IL-4 Empowered Superkine with Fast Track and Orphan Drug designations that has completed five clinical trials including Phase 2b for recurrent glioblastoma and is Phase 3-ready, early-stage IL-2/IL-15 super-antagonists from the MDNA209 platform for autoimmune and graft-versus-host diseases, BiSKITs (Bifunctional SuperKine ImmunoTherapies), and T-MASK (Targeted Metalloprotease Activated SuperKine) programs to target immunologically cold tumors. Founded in 2013 and headquartered in Toronto, Ontario, Canada, the company operates primarily in North America and Europe with a focus on immuno-oncology and neuroinflammatory therapies targeting unmet needs in high-grade gliomas, solid tumors, and inflammation. Recent developments include pursuing strategic partnerships for the Phase 3-ready bizaxofusp program in recurrent glioblastoma following testing in 118 high-grade glioma patients, advancing the Phase 1/2 ABILITY-1 trial of MDNA11 with topline monotherapy and combination data anticipated by year-end 2025 including expansion cohorts, completing enrollment in the ABILITY-1 study, and entering a collaboration with Fondazione Melanoma Onlus in November 2025 to sponsor the NEO-CYT randomized neoadjuvant trial evaluating MDNA11 in combination before first-line therapy for high-risk early-stage melanoma, alongside reporting fiscal year 2025 financial results in June 2025 and planning completion of the MDNA113 non-human primate study.
Company News
Medicenna Announces Results of Annual General and Special Meeting of Shareholders
Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting
Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences
Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
Medicenna Announces the Finalization of the Terms of its Public Offering of Securities
Medicenna Announces the Launch of a Marketed Public Offering of Securities
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026
Medicenna Therapeutics Announces Participation in Upcoming Conferences
Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
Medicenna Announces Changes to Board Composition
Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook
Medicenna Therapeutics Corp. (MDNA:CA) Discusses New Clinical Data From ABILITY-1 Study Evaluating MDNA11 in Cancer Immunotherapy Transcript
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors